Merck

Es una imagen que deben montar con Deamon Tools o cualquier unidad virtual, o quemar en un cd con el nero o uno similar.Parte 1.Parte 2.Parte 3.Parte 4.

Merck & Co., Inc. (NYSE: MRK) today outlined its drug pipeline and has reaffirmed its guidance given last week. Merck plans to emerge next year and into the... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

MSD simply stands for Merck, Sharp & Dohm.

Descargar Aquì.

India Infoline on PROCTER & GAMBLE - Target RS 901 India Infoline has recommended a ‘buy’ rating on Procter & Gamble with a one-year price target of Rs 901 after factoring in the 25% yearon-year growth in the net sales of the company and 42.50% rise in net profit. “Procter & Gamble registered 24.8% YoY growth in reve-nues at Rs 1.9 billion, led by strong growth in the health an

Shah added to his holdings in Merck & Co. Inc. by 40.73%. The impact to his portfolio due to this purchase was 1.04%. His holdings were 22,371,200 shares as of 09/30/2008.Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medica

Yesterday, drug giant, Merck, announced that it was cutting 7,500 jobs, and it’s a sure bet that most of those job eliminations will be in the sales positions. The unfortunate sales reps who lose those jobs will feel acute loss in their income and maybe even their lifestyle, but the brutal fact is that they will not be missed by either their company (Merck) or the physicians and the greater medi

Descargar Aquí.

Now this looks very interesting, three pharma big wigs getting together for something they have in common. The firm would cater to the niche requirement these pharmas have in the area of drug discovery. Enlight Biosciences will them the power to speed development of drug-discovery tools. The three pharmas and PureTech have ponied up a total of $39 million that Enlight will direct toward “brea

The drug Gardasil--a vaccine from Merck & Co. Inc. manufactured to inoculate women against HPV and cervical cancer--is possibly killing women instead.According to the U.S. Center for Disease Control (CDC) website, the CDC's Vaccine Adverse Event Reporting System (VAERS) "is a national program of CDC and the Food and Drug Administration (FDA) that monitors the safety of vaccines after they are

<!-- Converted from text/rtf format --> Investment Rationale ➢➢MIL, 51% subsidiary of Merck KGaA – Germany, operates in Pharmaceutical and Chemical segments. ➢➢Giving more thrust to top-line growth to achieve significant scale thru deeper penetration with increased field force, selective new launches from the parent and some line extensions in pharmaceutical se

<!-- Converted from text/rtf format --> Investment Rationale ➢➢MIL, 51% subsidiary of Merck KGaA – Germany, operates in Pharmaceutical and Chemical segments. ➢➢Giving more thrust to top-line growth to achieve significant scale thru deeper penetration with increased field force, selective new launches from the parent and some line extensions in pharmaceutical se

Thanks to everybody who entered to win a copy of the Merck/Merial Manual for Pet Health. I wish we could give one to everybody who entered, but we only had a few to give away. Here are the winners… Gary P, from San Jose, CA Stacey S, from New York, NY Nancy N, from Tiffin, OH Congrats to our [...]

“Is it time to start looking at pharma as a value play and buy some shares?” — Rick Pendergraft, Early to Rise by Rick Pendergraft Baltimore – (TFN): As a result of the legal issues big-name companies like Pfizer (PFE) and Merck (MRK) have been dealing with, the pharmaceutical [...]

Merck Serono announced today that its product, Rebif (interferon beta-1a) is celebrating its 10th anniversary this year. Since receiving approval for the treatment of relapsing-remitting multiple sclerosis 10 years ago in the European Union, as well as in Canada and Switzerland, Rebif has become a foundation therapy for MS.Elmar Schnee, President of Merck Serono said: "The introduction of Rebif(R)

I reviewed The Merck/Merial Manual for Pet Health a while back and am happy to be able to offer it to three of our readers. It’s an excellent source of information covering health issues for cats, dogs, horses, birds, and other animals. It’s based on the The Merck Veterinary Manual, but is written in a [...]

Bad news: Merck has decided to close down its natural product research facilities. This means the end of CIBE (Centro de Investigación Básica de España) — or Spanish Center for Biological Research — located in Madrid, Spain. Since its creation in 1954, this center has been dedicated to the discovery of new compounds of therapeutical potential produced by microbes. These efforts led to the d

Report Date May 23, 2008 Company Name Merck India Limited (MIL) Price / Recommendation Rs. 352.50 BUY   Sector Pharmaceutical One Year Target Price Rs. 525/- Market Capitalisation Rs. 594 crore 52–week range Rs. 310-460 Shares in issue (mio.) 16.86 BSE Ticker 500126 NSE Ticker MERCK BSE Sensex 16907.11   Shareholding Pattern on Mar. 2008 % Promoters 51.00% FIIs 1.20% MFs / UTI 5

DescriptionThe Merck Index Version 13 CD-ROM (Academic) It is actually 13th ediciton not the 13.4. By Publisher: WileyNumber Of Pages: Publication Date: 2001-06-30Sales Rank: 1255371ISBN / ASIN: 0471744018EAN: 9780471744016Binding: CD-ROMManufacturer: WileyStudio: WileyAverage Rating: Total Reviews: Book Description: The Merck Index Version 13.4 CD-ROM (Academic) is a single ele

Vaccine chief of Merck (massive drug company) admits that the HIV virus was imported to America through the use of HIV-infected African monkeys.Dr. Maurice Hilleman also acknowledges that the SV40 virus, which causes cancer, is being given through vaccines.

Ranbaxy Laboratories has signed a strategic product development agreement with German pharma major Merck for drug discovery and clinical development collaboration in the anti-infectives field. As per the deal, the two partners will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. The agreement is in line with Ranbaxy’s recent overtures for collaborati

Big Pharma continues to throw ballast out of the balloon in the hopes of staying aloft. The latest victim of declining fortunes in the industry is Merck (MRK),... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

A government conspiracy? AIDS, Cancer injected into us during a vaccination?? Population control without question...more videos about this treacherous act to come.

I just received a copy of The Merck/Merial Manual for Pet Health late last week, and even though I haven’t read it cover to cover (it’s 1,300 pages!) I highly recommend it to pet owners. It’s based on the The Merck Veterinary Manual, but is written in a layman’s terms so the average pet owner [...]

Merck & Co.'s (MRK) failure to win U.S. regulatory approval for a new cholesterol drug doesn't leave the drug maker down for the count, but it could make it harder to roll with the punches of generic competition in coming years. The Food and Drug Administration's rejection Monday of Cordaptive, just the latest setback for Merck this year, raises further concerns about how the drug giant will replace lost product sales in the coming years, and has led to a $9 billion reduction in the company's market value Tuesday. Those still bullish on the Whitehouse Station, N.J., company tout its respected research pipeline, new product sales and increasingly attractive dividend yield (thanks to the declining stock price). Nonetheless, Cordaptive was expected to be the basis for a franchise genera

Merck (MRK) had high hopes for its cholesterol drug Cordaptive According to The Wall Street Journal, things did not work out. The paper reports that the agency... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Pharmaceutical company Merck is currently fighting lawsuits brought by patients of their drug Vioxx, who claim the drug caused them to suffer severe health complications such as heart attacks and strokes. However, new allegations suggest that Merck may have known about the propensity of the drug to cause these health complications and kept the [...]

Among the companies whose shares are expected to see active trade in Monday’s session are Bank of America, Texas Instruments and Gannett. Bank of America Corp.’s (BAC) first-quarter earnings sank 77% to $1.21 billion, or 23 cents a share, as its provision for credit losses climbed and it posted $2.72 billion in net charge-offs. Net interest income rose to [...]

So you thought all those Vioxx studies in medical journals were independent, hands-off affairs? Not necesssarily. An examination of medical journal articles about Vioxx and court documents from Vioxx lawsuits found that Merck employees or ghostwriters were frequently involved in various articles, but the primary authors were often academics who actually had little to do [...]

Merck has announced its first quarter results. The company's Q1 net profit was at Rs 16.19 crore. Its net sales were at Rs 83.36 crore. Particulars8-Mar7-Dec7-Sep7-JunNet Sales / Interest Earned /... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

harma company Merck reported a marginal rise in standalone net profit for the first quarter ended March 2008. During the quarter, the profit of the company rose 1.61% to Rs 161.87 million from Rs 159.31 million in the same quarter, previous year. The company reported earnings of Rs 9.80 a share during the quarter, registering 3.70% growth over the corresponding quarter, previous year. Net sales for the quarter rose 18.40% to Rs 833.63 million, while total income for the quarter rose 18.07% to Rs 942.01 million, when compared with the prior year period.Merck has two major operating divisions - pharma and chemicals. Pharma business comprises of ethicals used in the treatment of cardiovascular and metabolic diseases, consumer healthcare products and vitamins. Chemicals business comprises of

Usually drug companies look forward to presenting data on their drugs and medical treatments. The the American College of Cardiology meeting was this weekend,... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

While Merck is wrapping up a series of clinical trials of diet drug Taranabant, which it expects to submit for FDA approval later this year, Pfizer has just launched a new Phase III trial of its diet drug CP-945,598, suggesting it may be considerably further away from being brought to market. Merck has two Phase III [...]

Merck Drug's Not Worth The WeightDiscouraging Phase III trial results on experimental obesity treatment. Link - Tue, 11 Mar 2008 07:12:26 GMT - Feed (2 subs) Sent using SendMeRss.com. Visit here to unsubscribe from "2-business" via X2 in Google. Recommended Feeds/Actions Subscribe MSNBC.com: Dateline video

Reuters makes some Interview with Merck #39;s chemicals business chief Walter Zywottek. He said that any serious commercial OLED application would not arrive before 2010. read more.

-- Company Announces Full-Year 2007 Non-GAAP EPS of $3.20 and Fourth-Quarter Non-GAAP EPS of $0.80, Excluding Certain Previously Disclosed Items; Full-Year GAAP EPS of $1.49 and Fourth-Quarter GAAP... Continued on JimCramerBlog.com

PT. Merck Tbk, A German based company leading in pharmaceutical and chemical business in Indonesia, is opening opportunity for energetic and motivated professional with high level of commitment, competence and dedication to the benefit of customer, to fill in the following positions: (more…) area manager, product manager, training manager

Merck plans to tell thousands of people who volunteered to test an experimental AIDS vaccine whether they received the actual shot or a placebo. The vaccine may have actually raised the risk of HIV infection. Two international trials of the vaccine were halted in September after it became clear that the vaccine did not prevent infection. In early November, researchers saw worrying indications that the vaccine could raised the risk of HIV infection, although they have asserted that the vaccine itself could not cause an infection. In many tests of new drugs, neither the researchers nor the volunteers know who gets the actual drug and who gets a placebo, in order to avoid any bias in determining how well the treatment works.Sources:Reuters November 13, 2007

Merck plans to tell thousands of people who volunteered to test an experimental AIDS vaccine whether they received the actual shot or a placebo. The vaccine may have actually raised the risk of HIV infection. Two international trials of the vaccine were halted in September after it became clear that the vaccine did not prevent infection. In early November, researchers saw worrying indications that the vaccine could raised the risk of HIV infection, although they have asserted that the vaccine itself could not cause an infection. In many tests of new drugs, neither the researchers nor the volunteers know who gets the actual drug and who gets a placebo, in order to avoid any bias in determining how well the treatment works.Sources:Reuters November 13, 2007

Merck plans to pay $4.85 billion to end as many as 50,000 lawsuits regarding its painkiller Vioxx. The deal, if accepted, would be one of the largest drug settlements ever. Merck pulled Vioxx from the market in 2004 after its was revealed that the popular drug doubled the risk of heart attacks and strokes. Before it was pulled, Vioxx may have resulted in 60,000 fatalities in the U.S. Merck executive vice president Kenneth Frazier called the agreement "responsible and reasonable," although Merck’s financial responsibility has been estimated as being as high as $50 billion. Negotiating teams in eight states have been working out this deal over the course of many months.To qualify to receive part of the settlement, plaintiffs must have presented medical proof that they suffered a heart attack or stroke, and that they received at least 30 Vioxx pills. Previously, Merck had attempted to claim that Vioxx caused harm only after 18 months of use, although these claimes were dismissed by inde

Merck plans to pay $4.85 billion to end as many as 50,000 lawsuits regarding its painkiller Vioxx. The deal, if accepted, would be one of the largest drug settlements ever. Merck pulled Vioxx from the market in 2004 after its was revealed that the popular drug doubled the risk of heart attacks and strokes. Before it was pulled, Vioxx may have resulted in 60,000 fatalities in the U.S. Merck executive vice president Kenneth Frazier called the agreement "responsible and reasonable," although Merck’s financial responsibility has been estimated as being as high as $50 billion. Negotiating teams in eight states have been working out this deal over the course of many months.To qualify to receive part of the settlement, plaintiffs must have presented medical proof that they suffered a heart attack or stroke, and that they received at least 30 Vioxx pills. Previously, Merck had attempted to claim that Vioxx caused harm only after 18 months of use, although these claimes were dismissed by inde

Merck has been testing a candidate HIV vaccine in two large phase II clinical trials; the STEP study in North and South America, the Caribbean and Australia, and a parallel study called Phambili in South Africa. STEP was a multi-center, randomized, double-blind, placebo-controlled phase II test-of-concept clinical trial. Started in December 2004, enrollment in the study was completed by March 2007 and more than 2,500 participants had received all three doses of vaccine or placebo. STEP was evaluating two primary efficacy endpoints: Whether the vaccine prevented HIV infection in subjects who were HIV negative at the beginning of the study. Whether the vaccine lowered the amount of virus in subjects who became HIV infected during the course of the study. However, last month the drug trial was halted because the vaccine appeared to be increasing the risk of HIV infection among study participants. The South African study Phambili, which began in 2007 using the same vaccine has been halt

It has been a bloody and bitter fight. Merck's (MRK) pain killer Vioxx has been alleged to cause heart problems and worse. The drug hit the market in 1999 and... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

GTx, Inc. (NASDAQ: GTXI) is seeing shares trade sharply higher on a collaboration pact with Merck... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

On Oct. 24th, Merck to Report Results for Acomplia Rival ,Taranabant At reunion ofThe Obesity Society’s annual scientific,which will be in New Orleans ,Merck is planning  to deliver on Wednesday, October 24th the first official report about the results of trials of its new diet drug Taranabant which works by blocking CB-1 receptors just as like Sanofi’s rimonabant(which can be bought online) . Is expected to present the report entitled “effects of taranabant(the rival of ,the drug that can be bought online,rimonabant), a new cannabinoid-1 receptor (CB-1R) inverse agonist, on patients with obesity over 12 weeks” the senior director of clinical research for Merck,Dr. Ngozi Erondu. The base of this report will be the results of Merck’s phase IIa trials of the diet drug,that was known then as L-000899055 or MK-0364. For the motiv that a phase III trial drug with 2,400 participants of the diet for nearly two years has been underway, this do

Seeking to recoup tens of millions spent by government-financed health programs on prescriptions for Vioxx, New York State and New York City joined yesterday in filing a lawsuit against Merck, the drug’s maker, which withdrew the painkiller from the market in 2004 because of dangerous side effects. The lawsuit, filed yesterday in State Supreme Court in Manhattan, accuses Merck & Company of intentionally concealing the dangers of Vioxx, and therefore defrauding the state Medicaid program, which paid for the prescriptions. The drug was used to treat arthritis and migraines but led to a high risk of heart attacks and strokes. New York Times September 18, 2007

The increased heart risk from Vioxx, Merck & Co's withdrawn arthritis medicine, begins much earlier than after 18 months of use, according to a study that contradicts assertions by the drug maker and its scientists. Reuters July 26, 2007

SCIENTISTS LINK DIABETES DRUG TO HEART FAILURE...The above pokes a cattle prod at Avandia once again (Glaxo SmithKline - GSK), and also Actos, manufactured by Japanese drug company Takeda.The bad press surrounding Avandia has been a boon for Merck (MRK) and its new drug Januvia (which I thought was a planet inhabited by the Januvians -- a stout and flatulent orange haired race -- in the 1960's Star Trek series). The bad Actos and Avandia news could also be good for the maker of Byetta - Amilyn (AMLN).This is serious stuff, actually. As a long time diabetic, I once took both Avandia and Actos and hated both the medications. I wonder if this is why I now take heart pills as well? Hmm, better jump into the class action lawsuit so I can collect my eventual settlement that will probably amount to no more than $1.65.

Four Lawsuits Filed against Merck for Osteoporosis Drug, Fosamax Anapol Schwartz Weiss Cohan Feldman & Smalley announce that the Firm has filed four lawsuits against Merck for osteonecrosis of the jaw caused by Fosamax. Philadelphia, PA (PRWEB) July 26, 2007 -- The Philadelphia law firm of Anapol Schwartz Weiss Cohan Feldman & Smalley has filed four lawsuits against Merck in NJ Superior Court, Middlesex County, New Brunswick NJ against the manufacturer of Fosamax (see: Stroup v. Merck - L-5869-07; Mahuron v. Merck - L-5863-07; Metcalf v. Merck - L-5836-07; & Sambrano v. Merck - L-5867-07). Fosamax is one of a class of drugs called bisphosphonates, which have been found to cause osteonecrosis of the jaw ("ONJ") or jaw bone death (See: Osteonecrosis of the Jaw and Bisphosphonates, N Engl J Med 2005;353(25):2728). Osteonecrosis of the jaw is a disabling and disfiguring jawbone condition that suffers literal death of the jaw or rotting of the jaw. ONJ is manifested

Merck, maker of osteoporosis drug Fosamax, may have “seriously underreported” risks of jawbone death related to the drug, according to the American Association of Oral and Maxillofacial Surgeons. A class-action lawsuit has been filed claiming that Merck knew about the risk of jawbone death but hid it from the public.Jawbone death related to the bisphosphonate class of drugs (to which Fosamax belongs), or Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ), is a serious side effect that destroys the bone in the jaw and is difficult to treat.BRONJ was reported by oral surgeons, who noticed the condition among patients treated with intravenous forms of bisphosphonates, in 2003. A broader warning of BRONJ was issued for the entire class of drugs in 2005.Fosamax is prescribed to about 10 million men and women -- mostly postmenopausal women -- each year to help increase bone density, with annual sales of $3 billion. Over 190 million prescriptions for oral bisphosphonate drugs have be

Merck, maker of osteoporosis drug Fosamax, may have “seriously underreported” risks of jawbone death related to the drug, according to the American Association of Oral and Maxillofacial Surgeons. A class-action lawsuit has been filed claiming that Merck knew about the risk of jawbone death but hid it from the public.Jawbone death related to the bisphosphonate class of drugs (to which Fosamax belongs), or Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ), is a serious side effect that destroys the bone in the jaw and is difficult to treat.BRONJ was reported by oral surgeons, who noticed the condition among patients treated with intravenous forms of bisphosphonates, in 2003. A broader warning of BRONJ was issued for the entire class of drugs in 2005.Fosamax is prescribed to about 10 million men and women -- mostly postmenopausal women -- each year to help increase bone density, with annual sales of $3 billion. Over 190 million prescriptions for oral bisphosphonate drugs have be

Drug developer Merck & Co. said Monday its second-quarter profit jumped nearly 12 percent on an across-the-board rise in drug sales, and the company boosted earnings guidance for the...

Word today of a multi-billion dollar deal in the generics industry. Mylan (MYL) is buying Merck KGaA's (not related to the present day U.S. based Merck-MRK) generics drug unit for over $6 bln. On the one hand, Mylan claims the deal will lead to "a dramatically accelerated growth profile with long-term compounded net income growth expected to exceed 30% per annum and long-term revenue growth in

Merck has seen some tumultuous times over the past year but even though it finally looks like it may be out of the doghouse with Friday’s dropping of a Vioxx litigation, recent buzz about the upgrade in Merck from SELL to NEUTRAL and in Merrill Lynch’s case from SELL to BUY, should all be taken lightly. “Merck & Co. (MRK) said late Friday a Texas court overseeing the Texas Vioxx litigations has rejected a plaintiff’s claim that she was not properly informed of the drug’s alleged risks. According to the company, the claim, which came in the case Ledbetter v. Merck, was rejected by the court because the Vioxx label contained a Food and Drug Administration-approved warning label.” The truth is there are still over 10,000 lawsuits in the pipeline and this ruling may be isolated. Even Merck’s strong performance this past week with Q1 earnings up 12% and net income up $0.09 a share to $1.7 billion from $1.52 billion in Q1 last year, will only p

Merck & Co. Inc. said Thursday its first-quarter profit jumped 12 percent, as the drugmaker posted sharply higher sales of its asthma and cholesterol drugs, plus one-time gains from product...

Merck & Co. Inc. said Thursday its first-quarter profit jumped 12 percent, as the drugmaker posted sharply higher sales of its asthma and cholesterol drugs, plus one-time gains from product...

Merck recently announced that it will collaborate with Hong Kong-based Chi-Med, a pharmaceutical firm that focuses on researching, developing, manufacturing and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients, to develop new cancer drugs. Traditional Chinese MedicineChinese herbal medicines have been used for centuries. Merck's partnership with Chi-Med was likely made with the intention of identifying the active ingredients in those medicines. Western pharmaceutical companies are increasingly outsourcing parts of drug discovery work due to the time and money - typically 7-10 years at a price of $800 million or more - required to find molecules to treat disease. The question is, when Merck patents the active ingredients in Chinese herbs, will it affect low cost, natural health practices? Hopefully, the answer will be no, since it’s speculated that any molecules id

Things have gotten so bad at Merck that they are renting ambulances for victims of the company's Vioxx drug and MRK sharesholders. Merck disclosed yesterday that it was in a dispute over $5.58 billion in taxes it may owe the US and Canada. Almost any child who reads a newspaper knows that Merck's Vioxx painkiller may cause heart problems and that the company is involved in countless suits that could cost it billions of dollars in damages. And now the taxman cometh. Merck has $6.2 billion in cash on its balance sheet, so, if it had to pay these taxes, it would not have a great deal left to cover Vioxx judgments, although future earnings could generate more cash. It is hard to figure out how the tax number could get so high. Merck's revenues are about $22 billion, so it is a pretty big bill. Merck's shares have recovered from the Vioxx shock. Its stock has recovered from a 52-week low of $27.99 to $45.90, near its high for the period. In 2003, the stock traded at $63. The tax issue i

From Peridot Capitalist Pharmaceutical giant Merck (MRK) is clearly looking for ways to boost growth. It's no secret that big pharma companies face increasing competition from generic drugs and pressure to keep rising healthcare costs in check. Small to mid size acquisitions of biotechnology companies are a solid way for companies like Merck, Pfizer (PFE), and Glaxo SmithKline (GSK) to strengthen their product pipelines. On Monday we learned that Merck is paying more than $1 billion for Sirna Therapeutics (RNAI). It's is quite possible that they overpaid. After all, MRK is paying $13 per share in cash, a premium of more than 100 percent over Monday's closing price. However, overpaying by a couple hundred million dollars isn't a big deal for a company the size of Merck if several of Sirna's products eventually reach the market. There is no doubt that deals like this one will continue. I am generally leery of trying to predict which firms will get taken out next. So, I would suggest

A company based in Germany, leading in pharmaceutical and chemical business in Indonesia. Looking for Export & Import Staff (Code: Exim) She/he shall be responsible in: Handling import & export activities Communicating with PPJK and supplier to ensure that import & export process runs well by ensuring all import & export documents are completed Ensure that permits related to import [...]

Staff Biologist - SCI003540 Job Description Submit Description Merck & Co. Inc., established in 1891, is a global research-driven pharmaceutical company... (From Merck)View Detail